Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 2
2002 8
2003 1
2004 2
2005 2
2006 3
2007 5
2008 1
2009 1
2010 2
2011 4
2013 4
2014 6
2015 9
2016 3
2017 3
2018 2
2020 4
2021 8
2022 8
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
[Exosomes and cancer].
de Vrij J, Maas SL, Hegmans JP, Lamfers ML, Dirven CM, Broekman ML. de Vrij J, et al. Among authors: lamfers ml. Ned Tijdschr Geneeskd. 2011;155(51):A3677. Ned Tijdschr Geneeskd. 2011. PMID: 22200143 Review. Dutch.
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Ntafoulis I, Kleijn A, Ju J, Jimenez-Cowell K, Fabro F, Klein M, Chi Yen RT, Balvers RK, Li Y, Stubbs AP, Kers TV, Kros JM, Lawler SE, Beerepoot LV, Kremer A, Idbaih A, Verreault M, Byrne AT, O'Farrell AC, Connor K, Biswas A, Salvucci M, Prehn JHM, Lambrechts D, Dilcan G, Lodi F, Arijs I, van den Bent MJ, Dirven CMF, Leenstra S; GLIOTRAIN consortium; Lamfers MLM. Ntafoulis I, et al. Among authors: lamfers mlm. Br J Cancer. 2023 Oct;129(8):1327-1338. doi: 10.1038/s41416-023-02402-y. Epub 2023 Aug 24. Br J Cancer. 2023. PMID: 37620410 Free PMC article.
Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial.
Bos EM, Binda E, Verploegh ISC, Wembacher E, Hoefnagel D, Balvers RK, Korporaal AL, Conidi A, Warnert EAH, Trivieri N, Visioli A, Zaccarini P, Caiola L, van Wijck R, van der Spek P, Huylebroeck D, Leenstra S, Lamfers MLM, Ram Z, Westphal M, Noske D, Legnani F, DiMeco F, Vescovi AL, Dirven CMF. Bos EM, et al. Among authors: lamfers mlm. Mol Cancer. 2023 Aug 10;22(1):129. doi: 10.1186/s12943-023-01835-6. Mol Cancer. 2023. PMID: 37563568 Free PMC article. Clinical Trial.
Developing oncolytic viruses for clinical use: A consortium approach.
Kemp V, Lamfers MLM, van der Pluijm G, van den Hoogen BG, Hoeben RC. Kemp V, et al. Among authors: lamfers mlm. Cytokine Growth Factor Rev. 2020 Dec;56:133-140. doi: 10.1016/j.cytogfr.2020.06.010. Epub 2020 Jun 10. Cytokine Growth Factor Rev. 2020. PMID: 32553482 Free article. Review.
New hints towards a precision medicine strategy for IDH wild-type glioblastoma.
White K, Connor K, Clerkin J, Murphy BM, Salvucci M, O'Farrell AC, Rehm M, O'Brien D, Prehn JHM, Niclou SP, Lamfers MLM, Verreault M, Idbaih A, Verhaak R, Golebiewska A, Byrne AT. White K, et al. Among authors: lamfers mlm. Ann Oncol. 2020 Dec;31(12):1679-1692. doi: 10.1016/j.annonc.2020.08.2336. Epub 2020 Sep 9. Ann Oncol. 2020. PMID: 32918998 Free article. Review.
79 results